Etiology and Outcomes of Pediatric Chest Pain in the ED: A Systematic Review
Abstract
Chest pain is a frequent complaint among children presenting to EDs, often raising concerns about underlying cardiac disease. This systematic review aimed to synthesize available evidence on the etiology, clinical outcomes, and prognosis of pediatric chest pain in ED settings. A systematic search of PubMed, BMJ Journals, Scopus, IEEE Xplore, and Web of Science was conducted to identify relevant studies. Studies reporting original data on children (<19 years) presenting with chest pain in ED settings were included. Study quality was assessed using the Newcastle-Ottawa Scale. Due to heterogeneity among the studies, a narrative synthesis of the findings was performed. Six retrospective studies comprising 14,871 patients from five countries met the inclusion criteria. Idiopathic chest pain was the most common etiology, accounting for 24.4%-45.4% of cases. Musculoskeletal (4.7%-33.0%), respiratory (2.9%-17.7%), and psychogenic causes (6.0%-21.6%) were also frequently reported. Cardiac etiology was rare in unselected populations (0.9%-1.5%), although a higher prevalence (7.1%) was observed in ambulance-attended cohorts. Hospitalization rates ranged from 0.3% to 7.2%, and cardiac interventions were required in fewer than 0.3% of patients. Mortality was reported to be below 0.2% across all studies. Five studies were rated as good quality, while one study was rated as fair quality. Pediatric chest pain in ED settings is predominantly benign, with idiopathic causes being the most…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 14,871 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.